All News
Links:
Factors Predictive of SLE Flare After HCQ Taper/Discontinuation
The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ? A recent study of five Canadian cohorts, suggests that certain baseline variables, including age, race, and steroid use, were predictive of flare in patients with SLE who tapered or discontinued treatment with hydroxychloroquine.
Read Article
Links:
RheumNow Podcast – Steroids, IVIG & the Vaccine (1.15.2021)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...
Read Article
2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read Article
Links:
ProDERM Study: IVIG in Dermatomyositis
The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).
Read Article
Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis
Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.
Read Article
Hydroxychloroquine Shortage During COVID-19
According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.
Read Article
Corticosteroid Use Hikes CV Risks in Rheumatic Patients
UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)
Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.
Read Article
Adherence to Hydroxychloroquine Lowers Lupus Mortality
A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.
Read Article
EULAR Guidance on Patient Adherence to Meds
Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens. EULAR has commissioned a task force
Read Article
Spinal Benefits Seen With Cosentyx in PsA
Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.
Read Article
Links: